Lipocine Inc
NASDAQ:LPCN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lipocine Inc
Other Long-Term Assets
Lipocine Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lipocine Inc
NASDAQ:LPCN
|
Other Long-Term Assets
$23.8k
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$8.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$17.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$17B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
Lipocine Inc
Glance View
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 13 full-time employees. The company went IPO on 2014-03-21. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The company has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.
See Also
What is Lipocine Inc's Other Long-Term Assets?
Other Long-Term Assets
23.8k
USD
Based on the financial report for Dec 31, 2025, Lipocine Inc's Other Long-Term Assets amounts to 23.8k USD.
What is Lipocine Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
2%
Over the last year, the Other Long-Term Assets growth was 0%. The average annual Other Long-Term Assets growth rates for Lipocine Inc have been 6% over the past three years , 4% over the past five years , and 2% over the past ten years .
